Our global life sciences company brings diagnostic testing & drug development together.

Viral Hepatitis Immunity Profile (HAV and HBV)

CPT: 86704; 86706; 86708


  • Hepatitis
  • Hepatitis A
  • Hepatitis B

Test Includes

Hepatitis A Virus (HAV) Antibody, Total; Hepatitis B Surface Antibody (anti-HBs); and Hepatitis B c Antibody (anti-HBc), Total

Special Instructions

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.

Expected Turnaround Time

1 - 2 days

Related Documents

Specimen Requirements


Serum or EDTA plasma


2.5 mL

Minimum Volume

1 mL (Note: This volume does not allow for repeat testing.)


Gel-barrier tube, red-top tube, lavender-top (EDTA) tube, plastic transport tube


If tube other than a gel-barrier tube is used, transfer separated serum/plasma to a labelled plastic transport tube. Do not freeze gel-barrier tube (pour off serum first).

Storage Instructions

Room temperature

Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Heat-inactivated specimens; cord blood; cadaveric specimens; or body fluids other than serum or EDTA plasma; gross hemolysis; excessive lipemia; improper labeling

Test Details


To access patients for immunity to Hepatitis A Virus (HAV) and Hepatitis B Virus (HBV). Detectable total anti-HAV antibody indicates immunity to HAV infection. Although usually not sensitive enough to detect the low level of protective antibody after vaccination, anti-HAV tests also might be positive after hepatitis A vaccination. The detection of anti-HBs antibodies in the absence of anti-HBc antibodies indicates immunity to HBV infection due to vaccination. The detection of both anti-HBs and anti-HBc antibodies indicates immunity due to natural infection.


The assays in this panel have not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, coed blood, or patients less than 2 years of age.


Immunochemiluminometric assay (ICMA)


Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020 Jul 3;69(5):1-38.32614811
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1)1-31.29939980
Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at